Gao L, et al. - Authors analyzed 969 eyes in 4 randomized controlled trials to examine the impacts and safety extent of dexamethasone implants and anti-vascular endothelial growth factor (VEGF) treatment for retinal vein occlusion (RVO). They observed improvement in Best-corrected visual acuity (BCVA) and more reduction in mean central subfield thickness (CST) in case of anti-VEGF therapy. While more unfavorable effects like higher intraocular pressure (IOP) and more incidents of cataracts were noted among cases with dexamethasone implants. They noticed no significant differences in conjunctival hemorrhage, reduced visual acuity (VA), and macular edema in both therapies. Overall, they concluded anti-VEGF therapy as a preferable treatment for RVO cases.